Johnson & Johnson (JNJ) Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision
Johnson & Johnson (NYSE: JNJ) FY 2026 Other Release
Analysis
Johnson & Johnson likely to report mixed results for Q1 FY26
Johnson & Johnson (NYSE: JNJ) ended fiscal 2025 on a high note, reporting higher revenues and strong earnings growth for...
Johnson & Johnson (JNJ) Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe
Johnson & Johnson (NYSE: JNJ) FY 2026 Other Release
Johnson & Johnson (JNJ) ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis
Johnson & Johnson (NYSE: JNJ) FY 2026 Other Release
ADVERTISEMENT
Johnson & Johnson (JNJ) FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide
Johnson & Johnson (NYSE: JNJ) FY 2026 Other Release
Johnson & Johnson (JNJ) Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer
Johnson & Johnson (NYSE: JNJ) FY 2026 Other Release
Johnson & Johnson (JNJ) Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients
Johnson & Johnson (NYSE: JNJ) FY 2026 Other Release
Johnson & Johnson (JNJ) Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line
Johnson & Johnson (NYSE: JNJ) FY 2026 Other Release
ADVERTISEMENT
Johnson & Johnson (JNJ) Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)
Johnson & Johnson (NYSE: JNJ) FY 2026 Other Release
Johnson & Johnson (JNJ) Q1 2026 Earnings Announcement
Johnson & Johnson (NYSE: JNJ) Q1 2026 Earnings Announcement